Azitra Inc.
Azitra develops a live biotherapeutic (ATR-04) for EGFR inhibitor-associated rash and a recombinant protein (ATR-COSF) for skincare.
8-KOct 1Latest SEC filing
Oct 1Latest story
Sign inSign inAzitra develops a live biotherapeutic (ATR-04) for EGFR inhibitor-associated rash and a recombinant protein (ATR-COSF) for skincare.
October 2026
September 2026
August 2026